ContractCollaboration Agreement • March 15th, 2018 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledMarch 15th, 2018 Company Industry JurisdictionCONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
DATED 28 FEBRUARY 2018Lease • March 15th, 2018 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledMarch 15th, 2018 Company Industry
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 15th, 2018 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledMarch 15th, 2018 Company IndustryTHIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “First Amendment”) is made effective as of October 30, 2017 (“Effective Date”) by and between Adaptimmune, LLC, a wholly-owned subsidiary of Adaptimmune Ltd. (“Company”), and Gwendolyn Binder-Scholl of Philadelphia, PA (“Executive”). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Employment Agreement (as defined below).